compound 37 [PMID: 36384290]   Click here for help

GtoPdb Ligand ID: 12256

Compound class: Synthetic organic
Comment: This compound is a KRAS-SOS1 interaction inhibitor that was designed for potential to treat KRAS-driven cancers [1]. It binds directly to SOS1 to disrupt the protein-protein interaction, and this action blocks guanine nucleotide exchange on KRAS and reduces KRAS activation.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 94.38
Molecular weight 536.21
XLogP 4.17
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES N#CC1(CC1)C(=O)N1CCN2[C@H](C1)COc1c2cc2c(nc(nc2c1)C)N[C@@H](c1cccc(c1F)C(F)F)C
Isomeric SMILES Cc1nc2cc3OC[C@@H]4N(CCN(C(=O)C5(C#N)CC5)C4)c3cc2c(N[C@H](C)c2cccc(C(F)F)c2F)n1
InChI InChI=1S/C28H27F3N6O2/c1-15(18-4-3-5-19(24(18)29)25(30)31)33-26-20-10-22-23(11-21(20)34-16(2)35-26)39-13-17-12-36(8-9-37(17)22)27(38)28(14-32)6-7-28/h3-5,10-11,15,17,25H,6-9,12-13H2,1-2H3,(H,33,34,35)/t15-,17-/m1/s1
InChI Key KKFFOOWORPUAJB-NVXWUHKLSA-N
References
1. Zhang S, Zhang Y, Chen X, Xu J, Fang H, Li Y, Liu Y, He H. (2022)
Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma.
J Med Chem, 65 (23): 15856-15877. [PMID:36384290]